tetano
Editor, Senior Moderator
Eur Rev Med Pharmacol Sci
. 2024 Jan;28(1):433-443.
doi: 10.26355/eurrev_202401_34932. A study survey on molnupiravir treatment in COVID-19 patients at home in Ninh Thuan province, Vietnam
T Le-Huy[SUP] 1 [/SUP], M G Balzanelli, P Thai-Phuong, T Tran Thai, H Nguyen Vu Ngoc, L Tran Phuc, T Le Quoc, T Nguyen Thanh, T Nai Thanh, T Le Van, L P Thi Bich, R Lazzaro, P Distratis, G Dipalma, R Morolla, A M Inchingolo, L Dongiovanni, F Triggiano, L Santacroce, R Del Prete, M Serafini, A Palermo, K Cao Diem Nguyen, F Inchingolo, C Gargiulo Isacco
Affiliations
Objective: Molnupiravir (MOV) is an oral antiviral drug that received use authorization in Vietnam for the treatment of mild COVID-19 (F0). There was a need to develop alternative approaches that allowed patients to access medication, decongest hospitals, clinics, and facilities, and protect people from infection. During the COVID-19 crisis, the Ninh Thuan Health Authorities implemented the home delivery of medication by community health workers. This study conducted in collaboration with two important Italian entities [the Aldo Moro University of Bari City and the 118 Department of Territorial Emergency System (118 SET) of Taranto City] aimed to evaluate the implementation of home delivery F0 treatment package assessing the rate of infection recovering during the coronavirus pandemic in Ninh Thuan province, Vietnam.
Patients and methods: A convergent mixed methods research, based on a longitudinal study with quantitative research and qualitative assessments, evaluated four implementation outcomes: the feasibility, fidelity, coverage, sustainability, and effectiveness of the initiative. Data sources included routinely collected data, a telephonic survey of patients, an analysis of set-up and recurrent costs, as well as descriptive exploratory qualitative and quantitative analysis.
Results: After taking the MOV for 5 days, only 35 out of the initial 400 F0 patients remained positive, while 365 patients (91.2%) were negative (CT≥30). Whilst, the successful rate after using the drug during the course accounted for 99.85% and 100% after the entire treatment course, without any death. After 5 days of taking the drug, a positive test result (CT<30) was associated with age group ≥60 (OR=2.7) and comorbidities (OR=3.0) (p<0.05) compared to negative and positive results (CT≥30). Negative factors impacting F0 at home include a shortage of healthcare workers, inadequate supply of thermometers and SpO2 meters, and insufficient financial support for healthcare workers.
Conclusions: MOV caused a reduction in the risk of hospitalization or death in mild COVID-19 patients, and molnupiravir was also found to be well tolerated and safe without any major adverse events during the administration period.
. 2024 Jan;28(1):433-443.
doi: 10.26355/eurrev_202401_34932. A study survey on molnupiravir treatment in COVID-19 patients at home in Ninh Thuan province, Vietnam
T Le-Huy[SUP] 1 [/SUP], M G Balzanelli, P Thai-Phuong, T Tran Thai, H Nguyen Vu Ngoc, L Tran Phuc, T Le Quoc, T Nguyen Thanh, T Nai Thanh, T Le Van, L P Thi Bich, R Lazzaro, P Distratis, G Dipalma, R Morolla, A M Inchingolo, L Dongiovanni, F Triggiano, L Santacroce, R Del Prete, M Serafini, A Palermo, K Cao Diem Nguyen, F Inchingolo, C Gargiulo Isacco
Affiliations
- PMID: 38235897
- DOI: 10.26355/eurrev_202401_34932
Objective: Molnupiravir (MOV) is an oral antiviral drug that received use authorization in Vietnam for the treatment of mild COVID-19 (F0). There was a need to develop alternative approaches that allowed patients to access medication, decongest hospitals, clinics, and facilities, and protect people from infection. During the COVID-19 crisis, the Ninh Thuan Health Authorities implemented the home delivery of medication by community health workers. This study conducted in collaboration with two important Italian entities [the Aldo Moro University of Bari City and the 118 Department of Territorial Emergency System (118 SET) of Taranto City] aimed to evaluate the implementation of home delivery F0 treatment package assessing the rate of infection recovering during the coronavirus pandemic in Ninh Thuan province, Vietnam.
Patients and methods: A convergent mixed methods research, based on a longitudinal study with quantitative research and qualitative assessments, evaluated four implementation outcomes: the feasibility, fidelity, coverage, sustainability, and effectiveness of the initiative. Data sources included routinely collected data, a telephonic survey of patients, an analysis of set-up and recurrent costs, as well as descriptive exploratory qualitative and quantitative analysis.
Results: After taking the MOV for 5 days, only 35 out of the initial 400 F0 patients remained positive, while 365 patients (91.2%) were negative (CT≥30). Whilst, the successful rate after using the drug during the course accounted for 99.85% and 100% after the entire treatment course, without any death. After 5 days of taking the drug, a positive test result (CT<30) was associated with age group ≥60 (OR=2.7) and comorbidities (OR=3.0) (p<0.05) compared to negative and positive results (CT≥30). Negative factors impacting F0 at home include a shortage of healthcare workers, inadequate supply of thermometers and SpO2 meters, and insufficient financial support for healthcare workers.
Conclusions: MOV caused a reduction in the risk of hospitalization or death in mild COVID-19 patients, and molnupiravir was also found to be well tolerated and safe without any major adverse events during the administration period.